Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Escalation, Single-Center, Open-label Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Adeno-associated Virus(AAV) Gene Therapy Product IPS101A in Parkinson's Disease Patients With Hoehn-Yahr Stage 4-5, Diagnosed in More Than 10 Years and Uncontrolled by All Available Monotherapy or Combination Therapy

NCT07371338 is registered in ClinicalTrials.gov with Innopeutics Corporation as lead sponsor.

NCT NCT07371338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Escalation, Single-Center, Open-label Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Adeno-associated Virus(AAV) Gene Therapy Product IPS101A in Parkinson's Disease Patients With Hoehn-Yahr Stage 4-5, Diagnosed in More Than 10 Years and Uncontrolled by All Available Monotherapy or Combination Therapy
Lead sponsor
Innopeutics Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
May 30, 2026
Completion date
December 31, 2027
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease, parkinson's disease